Good morning. Elizabeth Cooney here, sitting in for Ed Silverman again, wishing him sunny skies and delightful breezes if he’s walking the mascot somewhere off the Pharmalot campus. And coffee, of course. Here are some items to interest for the rest of us. …
Some scientists are questioning why Vertex, whose CRISPR therapy may have cured more than 70 clinical trial participants of sickle cell disease, has not released key information on precisely how CRISPR is affecting the DNA of patients in its trials, STAT writes. Not all scientists agree such information is crucial for investigating any adverse effects years down the road and a Vertex spokesperson said the company had done “extensive” work to understand and rule out risks and was confident in its approach.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
